Clinical Trials Sponsored by Aventura Hospital and Medical Center

Total 10289 results

Tianjin Medical University Cancer Institute and...

Unknown

A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma

Multiple Drug Use

China
Tianjin Medical University Cancer Institute and...

Unknown

the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake

Thyroid Diseases
Tianjin Medical University Cancer Institute and...

Unknown

Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice

Postoperative Complications
Tianjin Medical University Cancer Institute and...

Unknown

Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer

Carcinoma, Non-Small Cell Lung

China
Tianjin Medical University Cancer Institute and...

Unknown

A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy

Osteosarcoma
Tianjin Medical University Cancer Institute and...

Unknown

Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy

Squamous Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Withdrawn

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Completed

Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC

Non Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Hepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectable

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC

Advanced/Metastatic Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Single-center, Prospective Study on the Identification and Delineation of Brain and Lung Tumors and At-Risk Organs, and Functional Testing of Surrounding Tissues Based on Dual-Energy CT

Image Quality and Contouring Accuracy of the Tumor in Radiotherapy

China
Tianjin Medical University Cancer Institute and...

Recruiting

The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric Cancer

Gastric Cancer | No.12a Lymph Node Dissection

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery

Gastric Cancer | Predictive Cancer Model | Hepatic Metastasis

China
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma

Pancreas Cancer | Predictive Cancer Model

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients

PDAC - Pancreatic Ductal Adenocarcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

HER-2 Positive Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China
Tianjin Medical University Cancer Institute and...

Recruiting

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Intrahepatic Cholangiocarcinoma | Durvalumab | Gemcis

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Gastric Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Early Detection of Pancreatic Cancer

Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Chemotherapy

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma

Unresectable | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China
Tianjin Medical University Cancer Institute and...

Recruiting

Granisetron Transdermal Patch System for Prevention of CINV by CapeOX

Chemotherapy-induced Nausea and Vomiting

China
Tianjin Medical University Cancer Institute and...

Recruiting

Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation

Carcinoma, Non-Small-Cell Lung | EGF-R Positive Non-Small Cell Lung Cancer | Bevacizumab | Tyrosine Kinase Inhibitor

China
Tianjin Medical University Cancer Institute and...

Recruiting

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

First-line Treatment | Advanced Gastric Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma | HRD+Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

MSI-H Advanced Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

Colon Cancer | Immunotherapy | MSI-H | Adjuvant Therapy

China
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Locally Advanced Cervical Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma (KEYSTONE-003)

Pembrolizumab | Neoadjuvant Chemotherapy | Adenocarcinoma of Esophagogastric Junction

China
Tianjin Medical University Cancer Institute and...

Recruiting

Study on the Peristaltic Direction of GI Anastomosis in Roux-en-Y Reconstruction

Gastric Cancer | Peristaltic Direction | Roux-en-Y Gastrointestinal Anastomosis

China
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

Sintilimab, Cetuximab, Regorafenib,Combine,mCRC

China
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC

Lung Neoplasms | Lymph Node Excision

China
Tianjin Medical University Cancer Institute and...

Recruiting

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Breast Cancer | Fulvestrant | Palbociclib

China
Tianjin Medical University Cancer Institute and...

Recruiting

Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection (AdBTC-1)

Cholangiocarcinoma | Gall Bladder Carcinoma

China
Tianjin Medical University Cancer Institute and...

Completed

The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Active, not recruiting

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Gastric Cancer Stage IV

China

Clinical Trials Sponsored by Aventura Hospital and Medical Center

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations